362 related articles for article (PubMed ID: 26243587)
1. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
[TBL] [Abstract][Full Text] [Related]
3. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
[TBL] [Abstract][Full Text] [Related]
6. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
Grossi G; Viganò M; Loglio A; Lampertico P
Liver Int; 2017 Jan; 37 Suppl 1():45-51. PubMed ID: 28052621
[TBL] [Abstract][Full Text] [Related]
9. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.
Brancaccio G; Fasano M; Grossi A; Santantonio TA; Gaeta GB
Aliment Pharmacol Ther; 2019 Apr; 49(8):1071-1076. PubMed ID: 30793345
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
13. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
[TBL] [Abstract][Full Text] [Related]
15. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
16. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
[TBL] [Abstract][Full Text] [Related]
18. Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B.
Kim HS; Kim BK; Kim SU; Park JY; Kim DY; Song KJ; Park JW; Kim YJ; Baatarkhuu O; Han KH; Ahn SH
Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1647-1656.e6. PubMed ID: 27305847
[TBL] [Abstract][Full Text] [Related]
19. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
[TBL] [Abstract][Full Text] [Related]
20. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
Zoutendijk R; Reijnders JG; Zoulim F; Brown A; Mutimer DJ; Deterding K; Hofmann WP; Petersen J; Fasano M; Buti M; Berg T; Hansen BE; Sonneveld MJ; Wedemeyer H; Janssen HL;
Gut; 2013 May; 62(5):760-5. PubMed ID: 22490523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
